U.S. Markets close in 5 hrs 54 mins

Sanofi (SNY) in Focus: Stock Moves 5.5% Higher

Zacks Equity Research

Sanofi SNY was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $40.43 to $42.28 in the past one-month time frame.

The company has seen no estimate revisions over the past few weeks, while the Zacks Consensus Estimate for the current quarter remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Sanofi currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.  

Sanofi Price

Sanofi Price

Sanofi price | Sanofi Quote

A better-ranked stock in the Large Cap Pharmaceuticals industry is Bristol-Myers Squibb Company BMY, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is SNY going up? Or down? Predict to see what others think: Up or Down

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Bristol-Myers Squibb Company (BMY) : Free Stock Analysis Report
 
Sanofi (SNY) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research